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The accelerated discovery of disease-related genes emerging from genomic studies has strained 
the capacity of traditional genetically engineered mouse models (GEMMs) to provide in-vivo 
validation. Direct, somatic, genetic engineering approaches allow for accelerated and flexible genetic 
manipulation and represent an attractive alternative to GEMMs. In this study we investigated the 
feasibility, safety and efficiency of a minimally invasive, lentiviral based approach for the sustained 
in-vivo modification of renal tubular epithelial cells. Using ultrasound guidance, reporter vectors 
were directly injected into the mouse renal parenchyma. We observed transgene expression confined 
to the renal cortex (specifically proximal and distal tubules) and sustained beyond 2 months post 
injection. Furthermore, we demonstrate the ability of this methodology to induce long-term, in-vivo 
knockdown of candidate genes either through somatic recombination of floxed alleles or by direct 
delivery of specific shRNA sequences. This study demonstrates that ultrasound-guided injection of 
lentiviral vectors provides a safe and efficient method for the genetic manipulation of renal tubules, 
representing a quick and versatile alternative to GEMMs for the functional characterisation of 
disease-related genes.
Though genetically engineered mouse models (GEMMs) have been instrumental in modelling human 
disease for biological studies, they can be expensive, time-consuming and difficult to generate, espe-
cially when investigation of complex traits, like cancer, is required. Non-germline approaches allow for 
accelerated and flexible genetic manipulation of models permitting the study of multiple genes or gene 
combinations, and high-throughput functional genetic screens within the appropriate cell/tissue con-
text1. Lentiviral vectors represent an appealing tool for such approaches because of their ability to stably 
incorporate into the genome with high efficiency and have been successfully applied for the somatic 
genetic modification of a number of tissues2–4. Lentiviral vector delivery into the mouse kidney has been 
limited by the requirement for invasive surgical approaches involving exposure of the kidney and injec-
tion of viral preparations under direct visualisation5–7. Such approaches are technically demanding, time 
consuming and carry significant morbidity and mortality. Furthermore, studies to-date have examined 
only short time-points (days to weeks) following transduction. Approaches that allow long-term genetic 
modifications are essential for the in-vivo modelling of renal disease.
In this study we report the development and validation of a novel minimally invasive method for the 
in-vivo sustained genetic manipulation of the mouse renal tubular epithelium using lentiviral vectors and 
establish the feasibility of this approach as an alternative to traditional germline models.
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Results
Feasibility and safety of direct renal intraparenchymal delivery of lentiviral vectors using a 
minimally invasive, ultrasound-guided approach. To determine whether lentiviral vectors could 
be safely and efficiently delivered using a non-surgical approach we utilised a reporter third generation 
vector in which the expression of Luciferase and Strawberry fluorescent protein is driven by the consti-
tutive EF1a promoter (ELS lentiviral vector, Fig. 1a). We performed single, low volume (10 μ l) ultrasound 
(US) guided microinjection into the left renal parenchyma of adult (8 week, n = 5) and neonatal (7-12 
day, n = 5) C57BL/6 mice (Fig.  1b). Each procedure lasted a maximum of 15 minutes and all injected 
mice recovered well post anaesthesia with no adverse events observed. Histopathological examination of 
both adult and neonatal kidneys at 7, 15 and 60 days post transduction did not reveal any morphological 
alterations or infiltrations within the renal parenchyma suggesting the absence of a persistent inflamma-
tory response secondary to lentiviral infection.
To establish lentiviral vector integration and transgene expression in-vivo bioluminescence was 
assessed at 7 days post US-guided intraparenchymal injection. Luminescence was successfully detected 
from the left flank of ELS injected mice but not from litter-mates injected with a control (no luciferase) 
lentiviral vector (Fig. 1c). Furthermore, immunohistochemical analysis of injected kidneys at 7, 15 and 
60 days post infection revealed sustained Strawberry expression limited to the renal cortex and corticom-
edullary junction (Fig. 1d), supporting stable lentiviral integration and transgene expression.
Figure 1. Efficient and sustained renal tubular gene delivery via Ultrasound-guided intraparenchymal 
injection of lentiviral vectors. (a) Diagram of pELS lentiviral construct. LTR, long terminal repeat; RRE, 
Rev response element; cPPT, central polypurine tract; EF1, elongation factor 1 alpha promoter; E2A, self-
cleaving 2A peptide; WPRE, Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element. (b) 
Representative ultrasound images of left renal parenchymal injections in adult mice. White arrow shows 
kidney location, arrow tip points to the injection needle. (c) Whole body bioluminescence of kidney-specific 
luciferase expression in representative C57/BL6J mice that underwent ultrasound-guided left intrarenal 
injection of either ELS or control (no luciferase) lentiviral vector (left hand mouse) at 7 days post injection. 
The relative luminescence intensity is indicated by a colour scale bar. (d) Representative immunofluorescent 
images of renal sections of adult (top panels) and neonatal (bottom panels) ELS injected and control 
(uninjected) kidneys, 60 days post infection. Strawberry expression was limited to the renal cortex and 
corticomedullary junction. Cor, cortex; Med, medulla. Scale bars, 50 μ m.
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Cell and tissue specificity of lentiviral transduction. Cell type and tissue specificity of trans-
duction was determined both at 15 and 60 days post injection. Co-localisation studies revealed prefer-
ential infection of mainly proximal renal tubular epithelial cells, with lesser infection rates detected in 
distal tubules and fibroblasts (Fig.  2a). Collecting ducts and podocytes were spared (Fig.  2a). Though 
no reporter expression could be detected in the liver, spleen or lungs of injected animals, Strawberry 
expression was seen in the contralateral (right) kidney and in the epithelium of the urinary bladder 
(Fig. 2b), suggesting the occurrence of trans-ureteric but not haematogenous viral spread. To evaluate the 
extent of renal lentiviral transduction achieved by our approach, we examined multiple sections of both 
left and right kidneys of injected mice. Widespread cortical expression of Strawberry was observed at 
multiple levels throughout both kidneys further supporting lentiviral diffusion within the kidneys most 
likely through the ureteric system.
The age of mice at the time of the procedure did not influence the observed level, extent, cell or tissue 
specificity of lentiviral transduction.
Figure 2. Intraparenchymal delivery of lentiviral vectors preferentially infects epithelial cells of both 
kidneys and urinary bladder. (a) Confocal images of Strawberry expression in renal sections of ELS 
infected kidneys 60 days post injection. Sections were stained with the indicated antibodies and merged 
images with DAPI (blue) are presented. Preferential transduction was observed in proximal (AQP1) and 
distal (THP) renal tubular epithelial cells and renal fibroblasts (CD73) (white arrowheads). Strawberry 
was not localised to collecting ducts (AQP2) or podocytes (Nephrin) (white arrows). Scale bars, 50 μ m. 
(b) Confocal images of Strawberry expression in the liver, spleen, lung, urinary bladder and left and right 
kidney of ELS infected animals 60 days post left intrarenal injection (top panels) and uninjected control 
animals (bottom panels). Sections were stained with an antibody against Strawberry (green) and merged 
images with DAPI (blue) are presented. Scale bars, 50 μ m.
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Direct delivery of Cre-recombinase and RNAi for the sustained genetic modification of renal 
tubular epithelial cells. We next sought to investigate the potential application of this approach as an 
alternative to traditional germline mouse models of kidney disease. As our specialist interest lies in renal 
cancer research we chose to apply our methodology for the modification of genes known to be deleted 
in human renal cancer (VHL and TSC1).
We first examined the feasibility and efficiency of directly delivering Cre-recombinase and inducing 
conditional deletion of Vhl within renal tubular epithelial cells of GEMM, thereby bypassing the need for 
tissue specific germline Cre-alleles. We generated the lentiviral vector CCIE, in which the cytomegalovi-
rus promoter drives Cre-recombinase and the reporter GFP (Fig. 3a) and performed intrarenal injections 
in cohorts of mice homozygous or wild-type for the loxP-flanked Vhl allele8 (n = 21 and 4, respectively). 
Mice were analysed at 6, 12 and 16 months post-injection. Recombination of Vhl in kidneys of infected 
Vhlfl/fl mice and subsequent reduction in VHL protein levels within renal cortical lysates was confirmed 
by immunoblot (Fig. 3b). Vhl deleted kidneys were of normal external appearance and parenchymal mass, 
and did not display histological abnormalities in the structure of the renal tubules (Fig.  3c) consistent 
with previously published human and mouse data9–11. Furthermore, as seen in germline mouse models 
of biallelic renal Vhl deletion we observed accumulation of HIF1a (Fig. 3b), HIF2a and their downstream 
target CA9 (Fig.  3c)10,11, as well as an increase in cortical vascularisation (CD34 immunofluorescence, 
Fig. 3c)12. These results support the use of lentiviral intra-parenchymal delivery of Cre-recombinase as 
an alternative system for fast and efficient genetic modification of renal tubular epithelial cells.
Lentiviral systems also provide a safe and rapid approach for RNAi-mediated loss of function studies. 
As a proof of principle, we generated the lentiviral vector ERP, in which the reporter turbo-RFP and a 
mir30-shRNA sequence are driven by the EF1a promoter (Fig.  4a). Three shRNA sequences targeting 
the mouse Tsc1 gene, known to be mutated in renal cancer (shTsc1-1, shTsc1-2 and shTsc1-3) and an 
shRNA targeting luciferase (shLuc; control)13, were selected for further validation. Efficiency of TSC1 
knockdown was examined in-vitro in NIH3T3 and TB11381PDA cells (a mouse pancreatic adenocarci-
noma cell line); lentiviral infection with shTsc1-1 displayed the most efficient knockdown (~80%) and 
was selected for subsequent in-vivo experiments (Fig. 4b).
Five week old C57BL/6J mice underwent US-guided left intra-renal injection with ERP lentiviruses 
carrying either shTsc1-1 or shLuc (n = 10 and n = 5 respectively). Mice were analysed at 4 and 12 months 
post infection. No macroscopic or microscopic histological abnormalities could be detected in the kid-
neys of infected animals (Fig.  4c). Lentiviral transduction was confirmed by immunohistochemistry 
against turbo-RFP (Fig. 4c). TSC1 protein levels in the cortex of kidneys infected with the ERP-shTsc1-1 
virus were significantly reduced one year following lentiviral delivery (Fig.  4d,e). We observed a cor-
responding reduction in TSC2 levels (Fig.  4d) consistent with the role of TSC1 in stabilising TSC2 
protein levels14. The TSC complex is a key negative regulator of the mTORC1 complex15. Both in-vivo 
and in-vitro models have demonstrated that complete (biallelic) loss of TSC1 leads to the activation of 
mTORC1 and its downstream effectors (e.g. S6 ribosomal protein)16–18. To investigate the ability of the 
shTSC1-1 hairpin to induce complete TSC1 knockdown we performed immunohistochemical analyses 
of phospho-S6. No differences in renal phospho-S6 expression were detected between ERP-shTsc1-1 and 
ERP-shLuc injected animals (supplementary Fig. S1), suggesting the persistence of residual TSC1 protein 
within cells. Our results support the use of lentiviral vectors for safely and efficiently delivering shRNAs 
to the renal tubular epithelium resulting in the long term suppression of target proteins.
Discussion
In this study, we demonstrate that US-guided intraparenchymal delivery of lentiviral vectors can induce 
sustained genetic modification of renal tubular epithelial cells bypassing the need to engineer novel 
GEMMs and to breed multiple animals for the generation of compound mutants. A big advantage of our 
approach is its safety and efficacy. The use of US-guidance allows lentiviral delivery using a minimally 
invasive procedure with no consequent mouse morbidity or mortality. Furthermore, viral transduction 
was achieved in both neonatal and adult kidneys, allowing genetic manipulation of both developing and 
mature tubular systems. As with previously published studies, viral transduction was limited to the corti-
cal tubular epithelium with no infected cells seen in the glomeruli or medulla5–7. We also observed infec-
tion of urinary bladder epithelium and of the contralateral (uninjected) kidney but no infection within 
the liver, spleen or lungs of injected animals. These data support a model of transureteric viral spread 
which combined with the use of broad tropism lentiviral vectors (VSV-G pseudotyped) may have further 
enhanced the extent of transduction achieved by our model. Contralateral kidney transduction has been 
previously reported6, though of much lesser extent. This is most likely attributed to technical differences, 
as previous studies occluded the renal pedicle, essentially restricting the viral load to the injected kidney.
To our knowledge, this is the first study demonstrating sustained transgene expression at one year fol-
lowing renal lentiviral infection making it an attractive alternative to GEMMs for the study of chronic renal 
diseases and long-term outcomes. Using this approach we have successfully delivered Cre-recombinase 
and induced knockout of the Vhl gene in Vhlfl/fl mice reproducing the phenotype observed in GEMMs. 
Furthermore, delivery of shRNA sequences targeting Tsc1 resulted in sustained reduction of protein 
levels up to one year post infection. Though no phenotype was observed, this is likely to reflect the 
incomplete knockdown of TSC1 achieved by our shRNA sequence, most closely resembling in-vivo mod-
els of heterozygous Tsc1 loss. GEMMs with constitutive heterozygous loss of Tsc1 develop renal cysts 
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and lesions from approximately 12 months with most pathology being detected in 15-18 month old 
mice16–18. Longer follow-up or younger age at time of injection is likely to have allowed the development 
of pathology in our model. Alternatively, improvements in the efficacy of Tsc1 gene knockdown either by 
increasing the amount of delivered transgene (higher injected viral load or repeated viral injections) or 
by selecting alternative targeting approaches (like the recently described vectors mediating CRISPR-Cas9 
knockout of single or multiple genes19), could provide more robust and specific gene targeting.
The current sequencing efforts have greatly expanded our knowledge of the genetic landscape of 
human renal disease. Our proposed strategy of intraparenchymal lentiviral transduction offers flexibility 
and speed, allowing for rapid testing and functional validation of candidate renal tubular disease-causing 
variants and the elucidation of renal disease pathobiology.
Methods
Vectors and lentivirus production, purification and concentration. Constructs were cloned into 
the third-generation pBOBI lentiviral system that contains VSV-G and WPRE sequences for improved 
tropism and transgene expression (vector pTomo kindly donated by Prof Inder Verma, Salk Institute3). 
The pELS lentiviral vector was kindly donated by Dr Scott Lyons, University of Cambridge, UK. Maps 
of all vectors used are presented in supplemental Fig. S2. Briefly, to generate pCCIE, a Cre-recombinase 
fragment from the SV40CreERT2 vector20 and the CMV promoter and IRES-EGFP fragments of pTOMO 
were PCR amplified and inserted between the EcoRI and NotI (Cre-recombinase), PacI (CMV) and NotI 
(IRES-EGFP) sites of the pELS vector. To construct pERP, we amplified the tRFP-mir30 fragment of the 
pTRIPZ vector (Dharmacon) and inserted it into the NotI site of the pELS vector. Finally, a PGK-Puro 
cassette (kindly donated by Dr Scott Lyons, University of Cambridge) was inserted into the NheI site of 
Figure 3. In-vivo lentiviral delivery of Cre-recombinase to renal tubular epithelium results in 
recombination of target genes. (a) Diagram of pCCIE lentiviral construct. Cre, Cre-recombinase; 
IRES, internal ribosome entry site; GFP, Green fluorescent protein. (b) Anti-VHL, HIF1a and GAPDH 
immunoblots of renal cortical protein lysates from Vhlwt/wt and Vhlfl/fl mice intrarenally injected with CCIE. 
Samples were collected 12 months post infection with each column representing an individual mouse. Blots 
were cropped to improve clarity, full-length blots are presented in Supplementary Fig. S3a. (c) Histological 
images of renal sections from Vhlwt/wt and Vhlfl/fl mice intrarenally injected with CCIE at 12 months post 
injection (stains and antibodies as indicated). Scale bars, 100 μ m.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:11061 | DOi: 10.1038/srep11061
Figure 4. Efficient renal tubule-specific TSC1 knockdown using intrarenal lentiviral shRNA in-vivo. (a) 
Diagram of pERP lentiviral construct. EF1, elongation factor 1 alpha promoter; tRFP; turbo Red fluorescent 
protein; mir30, mir30-shRNA sequence; PGK, phosphoglycerate kinase I promoter; Puro, puromycin. (b) 
Anti-TSC1 and GAPDH immunoblots (left panels) and corresponding relative quantification of TSC1 
protein levels (right panels) of protein lysates of TB11381PDA (mouse pancreatic adenocarcinoma) and 
NIH3T3 cells infected with ERP harbouring Tsc1-specific shRNAs (shTsc1-1, shTsc1-2 and shTsc1-3) or 
control luciferase-specific shRNA (shLuc). Blots were cropped to improve clarity, full-length blots are 
presented in Supplementary Fig. S3b. (c) Representative histological images of renal sections from ERP-
shTsc1-1 and ERP-shLuc infected animals 12 months post left intrarenal injection and uninjected control 
animals (stains and antibodies as indicated). Scale bars, 100 μ m. (d) Anti-TSC1, TSC2 and GAPDH 
immunoblots of renal cortical protein lysates from ERP-shTsc1-1 and ERP-shLuc intrarenally infected mice. 
Samples were collected 12 months post infection with each column representing an individual mouse. Blots 
were cropped to improve clarity, full-length blots are presented in Supplementary Fig. S3c. (e) Relative 
quantification of TSC1 protein levels from renal cortical lysates of ERP-shTsc1-1 (n = 7) and ERP-shLuc 
(n = 4) infected mice at 12 months post injection. Data represent mean ± s.d. Differences between groups 
were assayed using Student’s t-test.
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the above vector. Target shRNA sequences were selected from published and on-line resources (supple-
mental Table S1) and cloned between the PspXI and EcoRI sites of the pERP vector.
VSV-G-pseudotyped lentiviral particles were produced as described previously21. All viral superna-
tants were concentrated approximately 100-fold by ultracentrifugation at 25,000 × g for 2 h. Lentiviral 
titres were established by infection of HEK293T cells with serially diluted virus and flow cytometry for 
fluorescence detection. We routinely produced 1–5 × 108 infectious units/ml.
In-vivo intraparenchymal vector injection. All animal work was carried out in accordance to 
Home Office UK regulations and the Animals (Scientific Procedures) Act 1986. All experimental pro-
tocols were approved by the Animal Welfare and Ethical Review Body (AWERB) of the University of 
Cambridge CRUK Cambridge Institute. We used the following mice: C57/BL6J (Charles River laborato-
ries), B6.129S4(C)-Vhltm1Jae/J (Jackson Laboratories). The Vevo 2100 (Visualsonics) with microinjection 
system was used for all procedures. Mice aged 7 days to 8 weeks old were anaesthetised with isofluorane 
and positioned prone on the ultrasound platform. Under high-resolution ultrasound guidance a bolus 
injection of 10 μ l viral solution was microinjected into the left renal cortex using a 30G needle and a 
50 μ l glass Hamilton syringe.
In-vivo bioluminescence imaging. Mice were anaesthetized with isofluorane and injected intraperi-
toneally with 10 μ l per g of body weight d-luciferin (15 mg/ml; Perkin-Elmer). Bioluminescence images, 
each typically 3 min, large binning, f/stop 1, were then taken 10–20 min post-luciferin injection, using 
an IVIS 200 series imaging system (Perkin-Elmer).
Histology and immunohistochemistry. At the experimental end-point animals were euthanized 
and tissues were fresh frozen in liquid nitrogen or fixed in 4% paraformaldehyde in PBS overnight. To 
review histology, slides were stained by haematoxylin and eosin (H&E). Immunohistochemistry (IHC) 
and immunofluorescence (IF) were performed using standard protocols. Specificity of immunostain-
ing was assessed by incubation in the absence of primary antibody. We used the following primary 
antibodies: RFP for Strawberry detection (ab34771, 1:400; Abcam), Aquaporin 1 (NB-600–749, 1:500; 
Novus Biologicals), THP (AF5175, 1:100; R&D), Aquaporin 2 (ab105171, 1:1000; Abcam), Nephrin 
(AF3159, 1:100; R&D), CD34 (ab8158, 1:50; Abcam), CD73 (AF4488, 1:100; R&D), GFP (ab290, 1:1000; 
Abcam), HIF2a (NB100-132, 1:150; Novus Biologicals), CA9 (sc-25600, 1:200; Santa Cruz), turbo-RFP 
(AB234, 1:500; Evrogen) and pS6 (2211, 1:200; Cell Signalling). Secondary antibodies used were conju-
gated to HRP (IHC) or Alexa-fluor® fluorochromes (IF). Fluorescent images were obtained by confocal 
laser-scanning microscopy (Leica TCS SP5).
Cell culture. HEK293T, NIH3T3 and TB11381PDA cells were cultured and maintained in Dulbecco’s 
modified Eagle’s medium supplemented with glucose and glutamine, with 10% FBS. For viral infections, 
NIH3T3 and TB11381PDA cells were plated in 96-well plates at 2,500 and 5,000 cells per well respec-
tively and incubated with lentivirus overnight. After 8 days, we positively selected infected cells with 
puromycin (4 μ g/ml) for 4 days and processed them for protein analyses.
Immunoblotting. Cells or tissues were lysed in RIPA buffer with protease and phosphatase inhib-
itors and lysates were processed using standard methods. We used the following primary antibodies: 
GAPDH (ab9485, 1:2000; Abcam), VHL (sc-5575, 1:250; Santa Cruz), HIF1a (NB100-105, 1:500; Novus 
Biologicals), TSC1 (ab32936, 1:500; Abcam), TSC2 (4308, 1:1000; Cell Signalling). Secondary antibod-
ies conjugated to IRDye 680 or 800 were used (Li-Cor). Fluorescent signals were quantified using the 
Odyssey Infrared Imaging System (Li-Cor).
Statistics. Quantitative data are expressed as mean ± s.d. Differences between groups were assayed 
using Student’s t-test. Differences were considered significant when p < 0.05. Statistical manipulations 
were performed in GraphPad Prism (GraphPad Software, Inc).
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